Guselkumab for checkpoint inhibitor–exacerbated psoriasis in a patient with metastatic melanoma
Clicks: 1
ID: 319751
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #149 of 171 articles by views in clinical and experimental dermatology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 171 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Severe pembrolizumab-exacerbated psoriasis in a patient with disseminated stage IV melanoma posed a significant therapeutic challenge. Guselkumab resulted in rapid clinical improvement (PASI 12.3 to 3.1; DLQI 21 to 3), allowing pembrolizumab rechallenge without recurrence of severe psoriasis. This case highlights the potential role of IL-23 inhibition in immune checkpoint inhibitor-induced psoriasis while emphasising uncertainty surrounding oncological outcomes in this setting.
| Reference Key |
openalex_W7167480916
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Olwyn J. Conlon, Maeve Herlihy, Yasmine Safta, YiXuan Goh, Aislinn Reilly, Adrian Murphy, Marina O’Kane |
| Journal | clinical and experimental dermatology |
| Year | 2026 |
| DOI |
10.1093/ced/llag280
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.